X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4607) 4607
Book Review (698) 698
Publication (249) 249
Magazine Article (51) 51
Conference Proceeding (9) 9
Book Chapter (7) 7
Book / eBook (4) 4
Trade Publication Article (2) 2
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (4046) 4046
humans (3923) 3923
male (2763) 2763
sildenafil citrate (1840) 1840
sulfones (1783) 1783
middle aged (1552) 1552
female (1402) 1402
sulfones - adverse effects (1290) 1290
adult (1277) 1277
piperazines - therapeutic use (1173) 1173
aged (1128) 1128
sulfones - therapeutic use (1113) 1113
purines (1038) 1038
piperazines - adverse effects (943) 943
erectile dysfunction - drug therapy (919) 919
sildenafil (880) 880
lactones - adverse effects (865) 865
animals (779) 779
treatment outcome (756) 756
abridged index medicus (657) 657
erectile dysfunction (635) 635
phosphodiesterase inhibitors - therapeutic use (623) 623
sulfones - administration & dosage (590) 590
pharmacology & pharmacy (583) 583
double-blind method (581) 581
urology & nephrology (577) 577
sulfones - pharmacology (555) 555
anti-inflammatory agents, non-steroidal - adverse effects (554) 554
cyclooxygenase inhibitors - adverse effects (547) 547
phosphodiesterase inhibitors - adverse effects (513) 513
piperazines - administration & dosage (486) 486
lactones - therapeutic use (461) 461
celecoxib (459) 459
medicine, general & internal (452) 452
purines - therapeutic use (424) 424
rofecoxib (420) 420
impotence (413) 413
risk factors (394) 394
drug therapy (383) 383
dose-response relationship, drug (378) 378
piperazines - pharmacology (376) 376
nonsteroidal antiinflammatory drugs (374) 374
vasodilator agents - therapeutic use (355) 355
cyclooxygenase inhibitors - therapeutic use (349) 349
anti-inflammatory agents, non-steroidal - therapeutic use (336) 336
vardenafil dihydrochloride (331) 331
double-blind (313) 313
safety (312) 312
administration, oral (311) 311
rats (310) 310
sulfonamides - adverse effects (303) 303
efficacy (301) 301
aged, 80 and over (300) 300
cyclooxygenase 2 inhibitors - adverse effects (295) 295
purines - adverse effects (292) 292
time factors (291) 291
analysis (277) 277
men (277) 277
prospective studies (275) 275
adolescent (271) 271
cardiac & cardiovascular systems (271) 271
cyclooxygenase 2 (258) 258
rheumatoid-arthritis (256) 256
hypertension, pulmonary - drug therapy (254) 254
care and treatment (253) 253
vasodilator agents - adverse effects (253) 253
erectile dysfunction - etiology (252) 252
oral sildenafil (245) 245
cyclooxygenase 2 inhibitors (241) 241
membrane proteins (235) 235
cox-2 inhibitors (234) 234
sulfonamides - therapeutic use (231) 231
drug therapy, combination (224) 224
tadalafil (223) 223
therapy (222) 222
drug interactions (221) 221
research (221) 221
mice (219) 219
imidazoles - therapeutic use (215) 215
hypertension (212) 212
purines - administration & dosage (212) 212
risk (209) 209
medicine & public health (205) 205
phosphodiesterase inhibitors - administration & dosage (204) 204
osteoarthritis (201) 201
united states (199) 199
randomized controlled trials as topic (197) 197
vasodilator agents - administration & dosage (194) 194
pyrazoles (192) 192
cross-over studies (189) 189
phosphodiesterase inhibitors - pharmacology (189) 189
nitric-oxide (187) 187
pulmonary hypertension (183) 183
clinical trials as topic (179) 179
health aspects (176) 176
membranes, artificial (176) 176
pyridines - adverse effects (176) 176
toxicology (176) 176
cyclooxygenase 2 inhibitors - therapeutic use (175) 175
cardiovascular diseases - chemically induced (174) 174
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4289) 4289
German (121) 121
French (58) 58
Spanish (46) 46
Chinese (39) 39
Japanese (24) 24
Russian (16) 16
Dutch (10) 10
Italian (10) 10
Norwegian (10) 10
Swedish (8) 8
Hebrew (7) 7
Finnish (6) 6
Czech (5) 5
Danish (5) 5
Portuguese (4) 4
Serbian (2) 2
Bulgarian (1) 1
Hungarian (1) 1
Polish (1) 1
Romanian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


American Journal of Physiology - Regulatory Integrative and Comparative Physiology, ISSN 0363-6119, 09/2014, Volume 307, Issue 6, pp. R693 - R703
20-Hydroxyeicosatetraenoic acid (20-HETE), Cyp4a-derived eicosanoid, is a lipid mediator that promotes tumor growth, as well as causing detrimental effects in... 
HET0016 | Stroke | Rofecoxib | Tumor growth | CARCINOMA-CELLS | PHYSIOLOGY | CANCER CELLS | THYMIDINE KINASE GENE | CARDIOVASCULAR EVENTS | 20-HYDROXYEICOSATETRAENOIC ACID FORMATION | ARACHIDONIC-ACID | stroke | CYP4A ISOFORMS | FORMAMIDINE HET0016 | rofecoxib | CEREBRAL-ARTERY OCCLUSION | tumor growth | CYCLOOXYGENASE-2 EXPRESSION | Hydroxyeicosatetraenoic Acids - antagonists & inhibitors | Colonic Neoplasms - drug therapy | Humans | Male | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Brain Ischemia - enzymology | Stroke - chemically induced | Time Factors | Lactones - administration & dosage | Brain Ischemia - chemically induced | Cyclooxygenase 2 Inhibitors - toxicity | Stroke - prevention & control | Sulfones - toxicity | Cytochrome P-450 CYP4A - metabolism | Cyclooxygenase 2 Inhibitors - administration & dosage | Cytochrome P-450 CYP4A - antagonists & inhibitors | Mice, Inbred C57BL | Rats | Brain Ischemia - prevention & control | Tumor Burden | Antineoplastic Combined Chemotherapy Protocols - toxicity | Lactones - toxicity | Stroke - enzymology | Dinoprostone - metabolism | Hydroxyeicosatetraenoic Acids - metabolism | Animals | Colonic Neoplasms - pathology | Cyclooxygenase 2 - metabolism | Cell Line, Tumor | Cell Proliferation - drug effects | Colonic Neoplasms - enzymology | Mice | Sulfones - administration & dosage | Index Medicus | Neural Control
Journal Article
Journal Article
Annals of Internal Medicine, ISSN 0003-4819, 10/2008, Volume 149, Issue 8, pp. 521 - 530
Background: Oral sildenafil and intravenous epoprostenol have independently been shown to be effective in patients with pulmonary arterial hypertension.... 
INHALED ILOPROST | SURVIVAL | MEDICINE, GENERAL & INTERNAL | ORAL SILDENAFIL | EFFICACY | TREPROSTINIL | SAFETY | COMBINATION THERAPY | PROSTACYCLIN | BOSENTAN | Piperazines - administration & dosage | Injections, Intravenous | Humans | Middle Aged | Sulfones - adverse effects | Antihypertensive Agents - administration & dosage | Hypertension, Pulmonary - physiopathology | Male | Dyspepsia - chemically induced | Purines - administration & dosage | Hemodynamics - physiology | Walking - physiology | Sildenafil Citrate | Time Factors | Epoprostenol - adverse effects | Adult | Female | Hypertension, Pulmonary - drug therapy | Purines - adverse effects | Drug Therapy, Combination | Headache - chemically induced | Double-Blind Method | Administration, Oral | Piperazines - adverse effects | Antihypertensive Agents - adverse effects | Adolescent | Quality of Life | Aged | Vasodilator Agents - adverse effects | Hypertension, Pulmonary - etiology | Vasodilator Agents - administration & dosage | Epoprostenol - administration & dosage | Sulfones - administration & dosage | Complications and side effects | Epoprostenol | Dosage and administration | Sildenafil | Drug therapy, Combination | Research | Drug therapy | Pulmonary hypertension | Hypertension | Inhibitor drugs | Patients | Quality of life | Index Medicus | Abridged Index Medicus
Journal Article
Circulation, ISSN 0009-7322, 06/2006, Volume 113, Issue 25, pp. 2906 - 2913
Background-The selective cyclooxygenase-2 (COX-2) inhibitors and other nonselective nonsteroidal antiinflammatory drugs ( NSAIDs) have been associated with... 
Drugs | Myocardial infarction | Cyclooxygenase-2 inhibitors | Mortality | Nonsteroidal antiinflammatory drugs | RHEUMATOID-ARTHRITIS | POPULATION | CARDIAC & CARDIOVASCULAR SYSTEMS | drugs | CARDIOVASCULAR EVENTS | myocardial infarction | CONVERTING ENZYME-INHIBITORS | RANDOMIZED CONTROLLED-TRIAL | CELECOXIB | BLOOD-PRESSURE | nonsteroidal antiinflammatory drugs | mortality | CYCLO-OXYGENASE-2 INHIBITORS | ROFECOXIB | PERIPHERAL VASCULAR DISEASE | BETA-BLOCKERS | HEMATOLOGY | cyclooxygenase-2 inhibitors | Ibuprofen - therapeutic use | Multivariate Analysis | Recurrence | Sulfones - therapeutic use | Confidence Intervals | Myocardial Infarction - mortality | Pyrazoles - therapeutic use | Patient Readmission | Humans | Middle Aged | Sulfones - adverse effects | Male | Dose-Response Relationship, Drug | Cyclooxygenase 2 Inhibitors - adverse effects | Cyclooxygenase 2 Inhibitors - therapeutic use | Aged, 80 and over | Female | Registries | Retrospective Studies | Odds Ratio | Pyrazoles - adverse effects | Diclofenac - therapeutic use | Diclofenac - adverse effects | Risk Factors | Proportional Hazards Models | Celecoxib | Lactones - adverse effects | Lactones - therapeutic use | Cross-Over Studies | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Myocardial Infarction - drug therapy | Sulfonamides - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Denmark | Sulfonamides - adverse effects | Aged | Ibuprofen - adverse effects | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2014, Volume 370, Issue 13, pp. 1189 - 1197
Ceritinib is 20 times as potent as crizotinib at inhibiting anaplastic lymphoma kinase (ALK) in vitro. In patients, ceritinib produced antitumor responses in... 
TRIALS | MEDICINE, GENERAL & INTERNAL | GEFITINIB | EML4-ALK FUSION GENE | MUTATION | ACQUIRED-RESISTANCE | CRIZOTINIB | CLINICAL RESISTANCE | KINASE INHIBITOR | STI-571 | EGFR | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Sulfones - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Young Adult | Recombination, Genetic | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | Carcinoma, Non-Small-Cell Lung - genetics | Pyrimidines - administration & dosage | Treatment Outcome | Sulfones - pharmacokinetics | Carcinoma, Non-Small-Cell Lung - mortality | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Maximum Tolerated Dose | Receptor Protein-Tyrosine Kinases - genetics | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Sulfones - administration & dosage | Antimitotic agents | Care and treatment | Dosage and administration | Research | Lung cancer, Non-small cell | Antineoplastic agents | Lung cancer | Diarrhea | Insulin-like growth factors | Dehydration | Kinases | Patients | Lymphoma | Gene amplification | Vomiting | Gene rearrangement | Hypophosphatemia | Antitumor activity | Mutation | Pharmaceutical industry | Protein-tyrosine kinase | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 4, pp. 452 - 463
Journal Article
by Zisman, David A and Schwarz, Marvin and Anstrom, Kevin J and Collard, Harold R and Flaherty, Kevin R and Hunninghake, Gary W and de Andrade, J and Frankel, S and Kaplan, R and Lancaster, L and Raghu, G and Utz, J.P and White, S.R and Zisman, David A and Brown, K.K and de Andrade, J and Kaner, R.J and King, T.E and Lasky, J.A and Loyd, J.E and Martinez, F.J and Raghu, G and Roman, J and Ryu, J.H and Noth, I and Zisman, D.A and Chapman, J and Olman, M and Lubell, S and Morrison, L.D and Steele, M.P and Haram, T and Roman, J and Perez, R and Perez, T and Utz, J.P and Limper, A.H and Daniels, C.E and Meiras, K and Walsh, S and Brown, K.K and Frankel, S and Kervitsky, D and Lasky, J.A and Ditta, S and de Andrade, J and Thannickal, V.J and Stewart, M and Zisman, D.A and Lynch III, J.P and Calahan, E and Lopez, P and King, T.E and Golden, J.A and Wolters, P.J and Jeffrey, R and Noth, I and Hogarth, D.K and Sandbo, N and Strek, M.E and White, S.R and Brown, C and Garic, I and Maleckar, S and Martinez, F.J and Han, M.L and Moore, B and Toews, G.B and Dahlgren, D and Raghu, G and Hayes, J and Snyder, M and Loyd, J.E and Lancaster, L and Lawson, W and Greer, R and Mason, W and Kaner, R.J and Monroy, V and Wang, M and Lynch, D and Colby, T and Becker, R.C and Eisenstein, E.L and MacIntyre, N.R and Morrison, L.D and Rochon, J and Steele, M.P and Sundy, J.S and Davidson-Ray, L and Dignacco, P and Edwards, R and Anderson, R and Beci, R and Calvert, S and Cain, K and Gentry-Bumpass, T and Hill, D and Ingham, M and Kagan, E and ... and The Idiopathic Pulmonary Fibrosis Clinical Research Network and Idiopathic Pulm Fibrosis Clinical and Idiopathic Pulmonary Fibrosis Clinical Research Network
The New England Journal of Medicine, ISSN 0028-4793, 08/2010, Volume 363, Issue 7, pp. 620 - 628
Journal Article
Journal Article